The clue in this story is the familial background of ‘eye worm’, indicating that she resides in a region with a high prevalence of Loa Loa.

Understanding Loiasis: A Filariasis Infection Caused by Loa Loa

Loiasis is a type of filarial infection that is caused by the Loa Loa parasite. This infection is transmitted by the Chrysops deerfly and is commonly found in the rainforest regions of Western and Central Africa. The clinical features of loiasis include pruritus, urticaria, and Calabar swellings, which are hot and non-erythematous swellings of soft tissue around joints. Another dramatic presentation of this infection is the subconjunctival migration of the adult worm, also known as the eye worm.

Compared to other microfilarial infections like Onchocerciasis and Lymphatic Filariasis, loiasis has fewer pathological features. However, high loa loa microfilaraemia can lead to encephalopathy following treatment with Ivermectin or DEC. This is due to the death of a large number of blood microfilaria. It is important to note that both of these drugs are contraindicated if loa loa microfilaraemia exceeds 2500 mf/ml. This has significant public health implications as Ivermectin is currently the drug of choice for controlling Onchocerciasis and Lymphatic Filariasis in Africa.

Strategies for Reducing Central Venous Catheter Blood Stream Infections

Central venous catheters (CVCs) are commonly used in medical settings, but they can pose a risk for blood stream infections. While prophylactic antibiotics have been used in the past, research has shown that they do not effectively reduce CVC blood stream infections. However, the use of semi-permeable polyurethane dressings is widely recommended as a preventative measure. Additionally, catheter impregnation has been shown to reduce the risk of both CVC blood stream infection and catheter colonization. It is important for healthcare providers to be aware of these strategies in order to minimize the risk of CVC-related infections. For further information on this topic, the article Central Venous Catheters by Smith and Nolan in the BMJ is a valuable resource.

When a patient with neutropenic sepsis fails to respond to broad-spectrum antibiotics within 48 hours, it is possible that they have a fungal infection. In this case, increasing G-CSF or administering paracetamol will not treat the infection. While adding metronidazole may be helpful, it is not clear if the source of the sepsis is abdominal. Further blood cultures may be necessary, but they will not improve the patient’s condition. The best course of action is to start fluconazole, as fungal causes should always be considered in cases of neutropenic sepsis. The patient’s oral candida and odynophagia suggest the possibility of oesophageal candidiasis, which should be taken into account given the presence of Candida.

Understanding Neutropenic Sepsis in Cancer Patients

Neutropenic sepsis is a common complication that arises from cancer therapy, particularly chemotherapy. It typically occurs within 7-14 days after chemotherapy and is characterized by a neutrophil count of less than 0.5 * 109 in patients undergoing anticancer treatment who exhibit a temperature higher than 38ºC or other signs of clinically significant sepsis. To prevent this condition, patients who are likely to have a neutrophil count of less than 0.5 * 109 should be offered a fluoroquinolone.

Immediate antibiotic therapy is crucial in managing neutropenic sepsis. It is recommended to start empirical antibiotic therapy with piperacillin with tazobactam (Tazocin) without waiting for the WBC. While some units add vancomycin if the patient has central venous access, NICE does not support this approach. After the initial treatment, patients are assessed by a specialist and risk-stratified to determine if they can receive outpatient treatment. If patients remain febrile and unwell after 48 hours, an alternative antibiotic such as meropenem may be prescribed, with or without vancomycin. If patients do not respond after 4-6 days, the Christie guidelines suggest ordering investigations for fungal infections (e.g. HRCT) instead of blindly starting antifungal therapy. In selected patients, G-CSF may also be considered.

Non-Falciparum Malaria: Causes, Features, and Treatment

Non-falciparum malaria is caused by Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, and Plasmodium knowlesi. Plasmodium vivax is commonly found in Central America and the Indian Subcontinent, while Plasmodium ovale is typically found in Africa. Plasmodium malariae is associated with nephrotic syndrome. Plasmodium knowlesi is found predominantly in South East Asia.

The general features of non-falciparum malaria include fever, headache, and splenomegaly. Cyclical fever every 48 hours is associated with Plasmodium vivax and Plasmodium ovale, while Plasmodium malariae is associated with cyclical fever every 72 hours. Ovale and vivax malaria have a hypnozoite stage and may relapse following treatment.

In areas known to be chloroquine-sensitive, the World Health Organization recommends either an artemisinin-based combination therapy (ACT) or chloroquine for treatment. In areas known to be chloroquine-resistant, an ACT should be used. However, ACTs should be avoided in pregnant women. Patients with ovale or vivax malaria should be given primaquine following acute treatment with chloroquine to destroy liver hypnozoites and prevent relapse.

Hypnozoite forms of P. vivax and ovale can lead to clinical illness even after patients have left the endemic region or may result in recurring disease after treatment.

Non-Falciparum Malaria: Causes, Features, and Treatment

Non-falciparum malaria is caused by Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, and Plasmodium knowlesi. Plasmodium vivax is commonly found in Central America and the Indian Subcontinent, while Plasmodium ovale is typically found in Africa. Plasmodium malariae is associated with nephrotic syndrome. Plasmodium knowlesi is found predominantly in South East Asia.

The general features of non-falciparum malaria include fever, headache, and splenomegaly. Cyclical fever every 48 hours is associated with Plasmodium vivax and Plasmodium ovale, while Plasmodium malariae is associated with cyclical fever every 72 hours. Ovale and vivax malaria have a hypnozoite stage and may relapse following treatment.

In areas known to be chloroquine-sensitive, the World Health Organization recommends either an artemisinin-based combination therapy (ACT) or chloroquine for treatment. In areas known to be chloroquine-resistant, an ACT should be used. However, ACTs should be avoided in pregnant women. Patients with ovale or vivax malaria should be given primaquine following acute treatment with chloroquine to destroy liver hypnozoites and prevent relapse.

Genital Ulceration in Rwanda: Likely Diagnosis and Differential Diagnosis

Genital ulceration is a common problem in Rwanda, and the most likely diagnosis is chancroid. This condition is caused by Haemophilus ducreyi, a Gram-negative rod that can lead to erythematous papules on the external genitalia and surrounding regions. These papules can later develop into pustules and haemorrhagic ulcers that are painful and often accompanied by lymphadenopathy.

While lymphadenopathy can also be seen in lymphogranuloma venereum and granuloma inguinale, these conditions have different presentations. LGV initially presents as a single painless ulcer, with secondary infection occurring two to six weeks later. Granuloma inguinale, on the other hand, is caused by Klebsiella granulomatosis and causes indolent painless ulcers. Regional lymphadenopathy is rare, and the incubation period is one to three months.

Although herpes simplex virus (HSV) is one of the most common causes of genital ulceration worldwide, it is less common than chancroid in Rwanda. In HSV, tender lymphadenopathy may be accompanied by systemic symptoms such as fever and headache.

In summary, chancroid is the most likely diagnosis for genital ulceration in Rwanda, but it is important to consider other conditions such as LGV, granuloma inguinale, and HSV in the differential diagnosis. Proper diagnosis and treatment are crucial for managing these conditions and preventing complications.

Membranoproliferative glomerulonephritis, which has led to acute kidney injury in this patient, can be caused by various factors. However, the significant factor in this case is the patient’s medical history of hepatitis C, which is strongly linked to mixed (type II) cryoglobulinaemia.

Cryoglobulinemia: Types, Features, Investigations, and Management

Cryoglobulinemia is a condition where immunoglobulins precipitate at 4 degrees Celsius and dissolve when warmed to 37 degrees Celsius. One-third of cases are idiopathic, and there are three types of cryoglobulinemia. Type I is monoclonal and is associated with multiple myeloma and Waldenstrom macroglobulinemia. Type II is mixed monoclonal and polyclonal and is usually associated with hepatitis C, rheumatoid arthritis, Sjogren’s, and lymphoma. Type III is polyclonal and is usually associated with rheumatoid arthritis and Sjogren’s.

Possible features of cryoglobulinemia include Raynaud’s, cutaneous vascular purpura, distal ulceration, ulceration, arthralgia, renal involvement, and diffuse glomerulonephritis. Investigations may reveal low complement, especially C4, and high ESR.

The management of cryoglobulinemia involves treating the underlying condition, such as hepatitis C, and immunosuppression. Plasmapheresis may also be used. Cryoglobulinemia can be a challenging condition to manage, but with proper treatment, patients can experience relief from their symptoms.

Overall, cryoglobulinemia is a complex condition that requires careful management and monitoring. By understanding the different types, features, investigations, and management options, healthcare professionals can provide the best possible care for patients with this condition.

The patient’s symptoms, including a rash, malaise, joint pain, and bilateral facial palsies, suggest a diagnosis of Lyme disease. This disease is caused by the bacterium Borrelia burgdorferi, which is transmitted through tick bites. The patient had been running in the countryside of Massachusetts, an area known to harbor Lyme disease, and may have been bitten by a tick. Diagnosis is made through serology for antibodies to B. burgdorferi, and treatment involves 2-3 weeks of oral doxycycline. Other potential diagnoses, such as secondary syphilis, cerebral toxoplasmosis, leprosy, and reactive arthritis, are less likely to explain the patient’s symptoms.

Antibiotics and their Mechanisms of Action for Lyme Disease Treatment

Lyme disease is a tick-borne illness that can be treated with antibiotics. The most effective treatment is doxycycline, a tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S subunit of ribosomes. Aminoglycosides also have a similar mechanism of action. Metronidazole damages bacterial DNA, but it is not used in the treatment of Lyme disease. Penicillin antibiotics disrupt cell membrane function by binding to and inhibiting proteins in the bacterial cell wall, but they are not used as first-line treatment for Lyme disease. Macrolides, such as erythromycin, clindamycin, and linezolid, block the 50S subunit of ribosomes, while quinolones, such as ciprofloxacin, inhibit DNA synthesis by binding to the enzyme DNA gyrase. Understanding the mechanisms of action of antibiotics can help in selecting the appropriate treatment for Lyme disease.

Investigations for a Patient with Hypocomplementaemia and Glomerulonephritis

When a patient presents with hypocomplementaemia and glomerulonephritis, it is important to investigate the underlying cause. In this case, the patient’s history and examination suggest infective endocarditis as the likely culprit. Serial blood cultures from different sites and an echocardiogram are the next investigations of choice. Treatment with intravenous flucloxacillin and gentamicin should be started immediately, without waiting for test results.

A computed tomography (CT) scan of the thorax and abdomen may be useful in identifying any malignancies or abnormal masses, but it is not helpful in diagnosing infective endocarditis. Similarly, tests for anti-double-stranded DNA antibodies, anticardiolipin antibodies, and rheumatoid factor are not useful in this context.

Overall, a careful evaluation of the patient’s symptoms and medical history, along with appropriate laboratory and imaging tests, can help identify the underlying cause of hypocomplementaemia and glomerulonephritis and guide effective treatment.